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Abstract: Reactions of innate immunity include phagocytosis, the production and activity 
of cytokines, chemokines, and adhesion molecules, the killing of infected or changed cells by 
NK cells and complement activated by natural lectins, and the cytokine-dependent resistance 
of leukocytes to viral infection. All these mechanisms maintain innate immunity. Deﬁ  ciency 
in this immunity is sometimes accompanied by frequent bacterial and viral infections. When 
innate immunity is permanently stimulated and the intensity of the reactions is stronger, these 
mechanisms may be directed against the host and subsequently stimulate acquired immunity 
(antibody and cellular immunity). A higher production of cytokines, oxidative stress, and a high 
production of NO accompany autoimmunity and neurodegeneration. The possible participation 
of innate immune receptors, cytokines, and other factors in the development of autoimmune 
and neurodegenerative diseases is discussed. The importance and possible role of blood-derived 
microglial cells in the prevention or elimination of amyloid deposits and plaque formation is 
described. A possible regulatory system, based on the presence of suppressors of cytokine 
signaling (SOCS), receptors of the Tyro-3 family, adenosine and adenosine phosphates, and 
IL-10, is reviewed. This review presents the mechanisms involved in the control of the innate 
immune response by microglia in the development of neurodegenerative disorders.
Keywords: innate immune reactions, deﬁ  ciency of innate immunity, over-stimulation, regula-
tion system, neurodegenerative disorders
Introduction
The mechanisms of protection against infection are mediated by two general systems: 
innate and adaptive immunity (Blach-Olszewska 2005). They differ in their detection 
systems (their receptors and the molecular structures of the pathogens detected), the 
cells engaged, and their functions. These two systems cooperate very closely. Recep-
tors of the innate system include Toll-like receptors (TLRs), stimulating receptors of 
natural killer cells (eg, NKG2D), and scavenger receptors (SRs). Moreover, natural 
lectins, such as mannose-binding lectin (MBL), collectins, and ﬁ  colins play roles as 
innate immunity receptors. All the receptors recognize pathogen-associated molecular 
patterns (PAMPs) as well as endogenous molecules (Johnson et al 2003).
Reactions of the innate immune system of vertebrates include:
•  phagocytosis of cells opsonized by natural lectins, with intracellular pathogen 
killing (oxygen burst) and efﬁ  cient removal of cellular debris (Lu et al 2002), 
•  the production and activity of cytokines, chemokines, adhesion molecules, and other 
agents such as defensins and NO (Blach-Olszewska 2005; Chang et al 2005), 
•  the killing of infected or changed cells by natural killers (NKs) or by the alternative 
or lectin-activated complement system (Carayannopoulos and Yokoyama 2004; 
Ferlazzo and Münz 2004; Fujita et al 2004),Neuropsychiatric Disease and Treatment 2007:3(3) 366
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•  the innate resistance of leukocytes and other cells ex vivo 
to viral infections (Orzechowska et al 2003; Paradowska 
et al 1996; Zaczyńska et al 1995).
In our laboratory, leukocyte resistance directed against 
viruses belonging to different taxonomic groups was found. 
It was reduced by addition of anti-IFNs and anti-TNFα anti-
body before viral infection and was also diminished in vitro 
in 1- to 5-day cell cultures. This resistance is thus one of the 
mechanisms of innate antiviral immunity. A test based on the 
resistance of leukocytes to viral infection was developed in 
our laboratory (Orzechowska et al 2003). The test is based on 
the kinetics of vesicular stomatitis virus (VSV) replication in 
freshly isolated peripheral blood leukocytes. When the titer 
of VSV reaches 0–1 log TCID50 innate immunity is good, 
when the titer is low (2–3 log) innate immunity is partial, and 
a high titer (>4 log) indicates low or deﬁ  cient immunity.
The correct functioning of such reactions as phagocy-
tosis, with successful removal of pathogens and pathogen-
infected cells or apoptotic bodies, a reasonable production 
of cytokines, cytokine-dependent leukocyte resistance to 
infections, and the indispensable killing of pathogen-infected 
cells by NKs and complement guarantee homeostasis in the 
organism. Sometimes, however, deﬁ  cient innate immunity 
is observed.
Deﬁ  cient innate immunity
A deﬁ  ciency in innate immunity might be an inheritable dis-
order. Toll-like or cytokine receptor signaling are involved 
in this pathology (Ku et al 2005). Mutations of genes for 
signaling proteins (IRAK4, MEMO, IκBα) are responsible 
for primary immunodeﬁ  ciency. Lower antiviral nonspe-
ciﬁ  c immunity of human leukocytes was observed in elderly 
blood donors’ leukocytes by Rybka and colleagues (2003). 
A deﬁ  ciency in the innate antiviral immunity of leukocytes 
is usually accompanied by remarkable sensitivity to viral and 
other infections and cancer diseases. Leukocytes of patients 
with frequent infections of the upper respiratory system or 
frequent incidences of herpes labialis showed deﬁ  ciency in 
innate immunity (Orzechowska et al 2003). The degree of 
innate immunity also inﬂ  uences the course of HCV infec-
tion (Unpublished data) and the progress of acute leukemia 
(Błach-Olszewska et al 2005). We found that the intensity of 
innate immunity is a prognostic factor for acute leukemia. All 
leukemic patients with complete innate immunity of leuko-
cytes at diagnosis achieved long-lasting complete remission 
after chemotherapy and are now in good condition. In contrast, 
there was no remission in patients with a deﬁ  ciency in innate 
immunity and all of them died 3–25 months after diagnosis. 
However, not only inefﬁ  ciency of the innate immune system 
is dangerous, but also its over-stimulation.
Over-stimulated innate immunity
Over-stimulation of the innate system with the engagement 
of TLR receptors, a higher production of cytokines, and a 
stronger killing of cells is supposed to be the reason for the 
extreme cell decline in, for example, virally infected liver or 
alcohol-related liver disease. The cachexia observed in AIDS 
patients is also probably connected with over-stimulation of 
the innate immune reaction by HIV (especially HIV gp120 
protein) and other opportunistic infections (our study showed 
extremely high resistance to VSV in leukocytes of AIDS 
patients). Over-activation of the innate immune system 
seems to be involved in the development of autoaggression. 
As reviewed by Rifkin and colleagues (2005), there is an 
increasing number of studies on the participation of innate 
immunity TLRs in the immune response in autoimmune 
diseases. Self molecules, largely originating from apoptotic 
bodies that have been altered in some way from their native 
state or which have accumulated in nonphysiological sites 
or amounts, are recognized by TLRs or by NKG2D present 
on NK cells. Defective or delayed clearance of these bodies 
might result in the release of autoantigens. According to 
Rifkin and colleagues (2005) this defect may be a primary 
effective cause of the development of autoimmunity. The 
proper production of cytokines, perhaps a constitutive 
production of interferons (IFNs) or TNFα by specialized 
cells, participates in maintaining innate immunity; however, 
when excessively produced, the cytokines may be directed 
against the host. Among the most important cytokines in 
innate immunity seem to be IFNs, cytokines of the TNF 
superfamily, and some interleukins. However, Baccala and 
colleagues (2005) consider IFNs type I and type II as the 
most pathogenic effectors in autoimmunity. According to 
the authors, these IFNs are the most pleiotropic molecules 
among the cytokines and primarily appear following adaptive 
immune responses through:
•  the up-regulation of MHC and costimulatory molecules,
• magniﬁ  cation of IFN production and signaling by cross-
talk among themselves,
•  their synergistic or antagonistic effects on other cytokines,
•  the direct or indirect initiation of transcription of immu-
nologically relevant genes.
A typical example of an autoimmune disease is myas-
thenia gravis. The contribution of autoantibodies directed 
against the acetylocholine receptor (AchR) present in the 
blood of most patients was considered to play a role in the Neuropsychiatric Disease and Treatment 2007:3(3) 367
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development of this disease. Neutralization of the receptor 
impairs the synaptic transmission of nerve signals and leads 
to muscle weakness. The effect of cytokines on acetylocho-
line receptor expression was studied by Poea-Guyon et al 
(2005), who found that AchR transcripts are up-regulated 
by IFNγ, and even the effect of IFNγ is more pronounced 
in the presence of TNFα. Up-regulated AchR, according to 
the authors, may initiate myasthenia gravis. By the effect 
of cytokines on AchR expression they proved the contribu-
tions of IFNγ and TNFα in the initiation of the autoimmune 
anti-AchR response.
An over-activated innate immune system may participate 
not only in the development of autoimmunity, but may also 
play a role in the pathogenesis of neurodegenerative diseases 
(Lehnard et al 2003; Jung et al 2005; Tanga et al 2005; 
Moisse and Strong 2006), lung ﬁ  brosis (Strieter and Keane 
2004), inﬂ  ammatory bowel disease (Elson et al 2005), and 
in the remodeling process in asthma (Cembrzyńska-Nowak 
et al 2005). In most neurodegenerative disorders, including 
Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, 
and AIDS dementia, massive neuronal cell death occurs as 
a consequence of an anarchic, uncontrolled inﬂ  ammatory 
response (Godbout et al 2005; Walker et al 2006). Addition-
ally, defective clearance of amyloid-β by macrophages of 
Alzheimer’s disease patients is observed (Fiala et al 2006). 
In the CNS, microglia play the role of resident phagocytic 
cells. Their physiological function is protecting neurons from 
invading microorganisms as well as removing products of 
cell degradation (Blais and Rivest 2003; Stolzing and Grune 
2004; Simard et al 2006). A critical role in this process is 
played by a receptor of the innate immune system, TLR4, 
and by cytokines, especially IFNβ (Jung et al 2005). How-
ever, over-activated innate immunity may also participate 
in the development of neurodegenerative diseases (Simard 
and Rivest 2005). Furthermore, blood-derived cells enter the 
brain in Alzheimer’s disease (AD) and in mouse models of 
the disease at increased frequencies (Togo et al 2002; Malm 
et al 2005). Apart from this characteristic neuropathology and 
the accompanying neurodegeneration, it has become clear that 
local immune responses involving glial cells and the comple-
ment system are activated in the AD brain as well (Wyss-
Coray 2006). When the microglia are permanently activated, 
for example by amyloid-β in AD or by the HIV protein 
gp120 in AIDS dementia (Rogers and Lue 2001; Townsend 
et al 2005), they cause inﬂ  ammation by the production of a 
variety of inﬂ  ammatory mediators. Through the activated 
TLR4-dependent pathway, the microglia product NO causes 
the degeneration of neurons. The neurodegenerative activity 
associated with NO production by microglia was found 
by Liberatore and colleagues (1999) in a murine model of 
Parkinson’s disease. According to Bate and colleagues (2006), 
prostaglandin D also mediates neuronal damage.
Regulation of innate immunity
As both deﬁ  ciency and over-activity of the innate immune 
system could be detrimental, a very effective regulatory 
system should exist in an organism. Up to now, possible 
mechanisms of upregulation have been partially described. 
Some constitutively expressed cytokines, such as the IFNs, 
and TNFα, are the endogenous stimulators of natural 
immunity (Paradowska et al 1996; Orzechowska et al 2003). 
Innate immunity is stimulated also by a neuropeptide known 
as substance P (SP). Lighvani and colleagues (2005), in 
studies on corneal resistance to Pseudomonas aeruginosa 
infection, showed that SP has a stimulatory effect on NK 
cell-induced IFNγ production through interaction with its 
receptor, NK-1R. SP is present in lymphocytes and the CNS 
and plays an important role in dendritic cell (DC) and mac-
rophage function. When innate immunity is over-stimulated, 
the reduction of riotous reactions should be regulated by 
control mechanisms. Possible effectors engaged in the control 
of innate immunity include:
•  suppressors of cytokine signaling (SOCSs),
•  the Tyro-3 family of receptors,
•  adenosine and adenosine phosphates,
•  the cytokines IL-10 and TGFβ,
•  soluble TLRs or cytokine-receptors.
Additionally, regulation on cell contact, ie, of NKs and DCs, 
is postulated. 
Many cytokines, eg, interferons, members of the TNF 
family, and the interleukins (IL-12, IL-18), take part in 
maintaining the innate immune system, so suppressors of 
cytokine signaling (SOCSs) may play an important role in 
controlling innate immunity (Elliott and Johnston 2004; 
Yoshimura 2005). These are members of a family of intra-
cellular proteins, and several of them have emerged as key 
physiological regulators of cytokine-mediated homeostasis. 
In the family of SOCSs are eight suppressors induced on 
cytokine stimulation. They then block further cytokine 
signaling. Signaling intermediates (JAK, STAT, or the 
intracellular receptor domain) are degraded next (Elliott and 
Johnston 2004). Takase and colleagues (2005) suggest that 
SOCS 5, which is constitutively expressed in the retina, may 
have a neuroprotective function, while the other cytokine-
induced SOCSs may be involved in the negative regulation 
of inflammatory cytokines during autoimmune uveitis. Neuropsychiatric Disease and Treatment 2007:3(3) 368
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Several authors (Kovarik et al 2005; Stark and Cross 2006) 
found that SOCS-1 and SOCS-3 are induced by cytokines 
such as IFNγ and IL-6. It is known that the cytokine level 
is up-regulated during experimental autoimmune encepha-
lomyelitis (EAE). Autoimmune process could be regulated 
by both molecules (SOCS-1 and SOCS-2). SOCSs not only 
inﬂ  uence cytokine and growth hormone signaling, but also 
the signaling pathway initiated by the reaction of a TLR with 
PAMP or an endogenous molecule. According to Mansell 
and colleagues (2006), SOCS-1 negatively regulates TLR 
signaling by mediating the degradation of the adapter protein 
Mal. This protein is involved in signaling via TLR-2 and 
TLR-4. Because of their obvious biological importance, the 
SOCS proteins have been the subject of intense investiga-
tion, including the development of strategies to utilize these 
proteins to control cytokine-induced JAK/STAT signal 
transduction for therapeutic purposes.
The cytokines IL-10 and TGFβ are known inhibitors of 
innate and adaptive immunity. Both directly affect macro-
phages; moreover, IL-10 indirectly inﬂ  uences Th1 and NK 
cells. Lang and colleagues (2002) studied the total effect 
of IL-10 on the transcriptional response induced in LPS-
activated macrophages. They found that TNF and several 
other cytokines and chemokines are considerably reduced 
in in vitro macrophage cultures and in vivo models where 
mice were challenged with TLR agonists. Moreover, they 
also found that IL-10 up-regulated the expression of the 
socs-3 gene. It is known that the SOCS-3 molecule blocks 
intracellular IFNγ and IL-6 signaling. The results of Qasimi 
and colleagues (2005) indicate that SOCS-3 is an important 
mediator of IL-10 inhibition of macrophage activation. 
Another cytokine, transforming growth factor β (TGFβ), 
acts as an autocrine regulator of macrophage function, 
and this regulation was not observed in TGFβ-null mice. 
TGFβ-deﬁ  cient mice had increased TLR expression and 
were hypersensitive to endotoxin. TGFβ’s regulatory role 
was conﬁ  rmed in experiments on mice lacking TGFβ, which 
developed multiorgan inﬂ  ammation due in part to abnormal 
innate cell responses.
Tyro-3 is another group of molecules with regulatory 
activity. Three members of the Tyro-3 receptor group: Tyro3, 
Axl, and Mer, belong to the tyrosine kinases. According to 
Lu and Lemke (2001) they are responsible for homeostatic 
regulation of the immune system. They regulate the function 
of the innate system by limiting the magnitude and extent 
of macrophage and dendritic cell activation after an initial 
immune stimulation. In the absence of this signaling system 
in TAM mice, macrophages are constitutively activated. In 
these mice lacking Tyro-3 receptors, elevated expressions of 
IL-2R, CD69, Fas, and IFNγ were observed. Tyro-3 kinase 
receptors play a role in the regulation of cytokine production 
as well as in phagocytosis and the removal of apoptotic cells 
(Cohen et al 2002). A remarkable diversity of autoimmune 
disease symptoms resembling rheumatoid arthritis, systemic 
lupus erythematosis, and other human autoimmune diseases 
are observed in mice lacking the c-mer membrane tyrosine 
kinase. Tyro3 receptors are expressed on some cells of the 
immune (Camenish et al 1999; Scott et al 2001; Cohen 
et al 2002), reproductive (Wong and Lee 2002; Wang et al 
2005), nervous (Prieto et al 2000), and vascular systems. 
The ligand molecules for these receptors are Gas 6 (growth 
arrest-speciﬁ  c gene-6) and protein S. Expression of the 
three receptors was shown to play a role in the developing 
rat central nervous system by Prieto and colleagues (2000). 
They were found on Purkinje cells, in granule neurons, and 
in Bergman glia. They were also detected in cerebellar white 
matter. Lu and Lemke (2001) noted that mutation of the 
mer gene in humans is associated with retinitis pigmentosa. 
All the studies indicate that Tyro-3 receptors are involved 
in the regulation of hyper-activated reactions of the innate 
immune system.
Adenosine and adenosine phosphates (ADP and ATP) 
belong to the regulatory mechanisms that limit damage 
caused by an overly increased immune response. The 
immunoregulatory effect of ATP on cytokine release from 
stimulated whole-blood cultures was observed by Swennen 
and colleagues (2005). Lower production of TNFα and 
higher IL-10 titer were observed in stimulated cultures treated 
with ATP. Such an effect was not observed, however, when 
adenosine was used instead of ATP. The protective effect of 
ATP against cachexia was conﬁ  rmed in clinical examination 
of patients with nonsmall-cell lung cancer (stage IIIB/IV) 
after regular infusions of ATP. The results showed that treat-
ment of patients with ATP was much better than palliative 
therapy alone (Agteresh et al 2000). The patients’ weight, 
muscular strength, and quality of life were much better than 
those of the latter group. Other authors pointed out adenosine 
as an endogenous regulator of innate immunity because of its 
negative regulatory role in NFκB and MAPK signaling. This 
purine nucleoside suppresses TNFα and IL-12 production 
(Hasko and Cronstain 2004; Ijon et al 2005; Antonieli et al 
2006; Kreckler et al 2006; Lee et al 2006). Similarly to ATP, 
IL-10 production by macrophages is potentiated by adenosine 
(Nemeth et al 2005). These results indicate that IL-10 may 
play a role as one of the mediators of adenosine and ATP inhibi-
tory activity. A purine nucleoside, adenosine is a biologically Neuropsychiatric Disease and Treatment 2007:3(3) 369
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active molecule that is formed at sites of metabolic stress 
associated with hypoxia, ischemia, trauma, or inﬂ  ammation. 
Because of this, Hasko and Cronstein (2004) called adenosine 
a “retaliatory metabolite”. Many of its effects are mediated 
through one or more of four receptors: A1, A2A, A2B, and A3, 
which are coupled with speciﬁ  c G protein. The receptors 
are expressed on monocytes, macrophages, dendritic cells, 
glial cells, and neurons (Hasko and Cronstein 2004; Lee et al 
2005; Zaidi et al 2006) and participate in adenosine-mediated 
regulation of immunity and inﬂ  ammation (Anonielli et al 
2006). These receptors, as described by Nemeth and col-
leagues (2005), are seven-membrane-spanning proteins that 
couple to heterodimeric G proteins and trigger a variety of 
intracellular signaling pathways.
In addition to the different mechanisms engaged in con-
trolling innate immunity, soluble receptors may also play 
a regulatory role. Le Bourder and colleagues (2003) found 
soluble TLR-2 in human plasma and breast milk and con-
sidered its role as a regulatory factor capable of modulating 
TLR2 signaling. Regulatory activity may also be a result of 
cell contact. Zitvogel (2002) reviewed that contact between 
immature DC and NK cells ﬁ  nally results in NK activation 
and DC maturation. After NK cell activation they start to 
proliferate and produce IFNγ. The ﬁ  nal result depends on the 
kinetics of NK activation. When NK cells are numerically 
dominant over immature DCs, the latter are killed. When the 
proportions of the cell populations are reversed, DCs undergo 
maturation and their resistance to NK killing is higher. In 
this way, both innate and acquired immunity are under the 
inﬂ  uence of cell-cell contact.
It indeed appears that chronic inﬂ  ammation may be a 
major driving force in the most important diseases our time: 
autoimmune and neurodegenerative disorders, especially 
AD (Simard and Rivest 2006). Age-related diseases such 
as Alzheimer’s are “the price we pay” for a life-long active 
immune system: this system also has the potential to harm 
us later as its ﬁ  ne tuning becomes compromised. We have 
much to learn about the innate immune system under these 
conditions. We need to explore the mechanisms whereby 
the innate immune system recognizes and targets both self 
and non self, just as we have investigated these issues in the 
adaptive immune system. We have every reason to believe 
that therapies that selectively modulate the functioning of the 
innate system will prove just as valuable as treatments that 
intervene with the adaptive immune system.
In conclusion, both a deﬁ  ciency in and an over-activation 
of innate immunity lead to health problems. A better 
understanding of the regulatory mechanisms helps us to 
understand the causes of autoimmune or neurodegenerative 




of Alzheimer’s type:   A possible 
therapeutic approach
Over the past twenty years, evidence has been accumulating 
that there is a chronic inﬂ  ammatory reaction in areas of the 
brain affected by Alzheimer’s disease and other types of neu-
rological disorders (eg, ischemia, spinal cord injury, multiple 
sclerosis, prion diseases, Parkinson’s disease, epilepsy). At 
present there seems to be no doubt that neuro-immune mecha-
nisms contribute actively to the neurodestructive process 
located in the senile plaques of the AD brain. The senile 
plaques of AD patients contain deposits of many immune-
reaction soluble factors (Rogers 1995). Among them, comple-
ment proteins, from the initial component C1q through the 
terminal cytotoxic C5b-C9, the complement receptors CR3 
and CR4, and complement inhibitors, cytokines and interleu-
kins (TNF-alpha, IL-1, IL-2, IL-6), and acute phase reactants 
(alpha1-antichymotrypsin and alpha2-macroglobulin) were 
exclusively localized in AD plaques. 
Immune cells are present around senile plaques (Wenk 
2003). Staining with a monoclonal antibody speciﬁ  c for 
activated microglial cells revealed a marked increase in these 
cells in the rims of senile plaques (Dik et al 2005). It seems 
to be proved that these cells secrete beta-myloid protein 
and are responsible for the alternative pathway cleavage of 
beta-amyloid precursor protein to yield amyloidogenesis 
fragments in AD senile plaques (Dziedzic 2006). A common 
feature of AD is the abundance of activated microglia in the 
proximity of neuritic plaques (Akiyama et al 2000). Activated 
microglia cells released interleukins 1 and 6, TNF-alfa and 
complement proteins (McRae et al 1993). They can also be a 
source of potentially cytotoxic metabolites, including reactive 
oxygen intermediates and nitric oxide (Walker et al 2006). 
It was also suggested that microglia produce and release 
anti-brain-tissue antibodies of the IgG class that recognize 
different neuronal structures and can activate the complement 
cascade by the classical pathway (Nagele et al 2004).
The presented above data strongly suggest that autoim-
mune reactions are present in every case of AD. Therefore, 
immunosuppression should be the treatment of choice. 
Such treatment can decrease inﬁ  ltration of the rims of senile 
plaques by immune cells and also lead to a diminution in Neuropsychiatric Disease and Treatment 2007:3(3) 370
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the release of cytokines and soluble inﬂ  ammatory factors. 
Steroids seem to be improper candidates for immunosuppres-
sive therapy of AD, since marked changes in the cytosolic 
glucocorticoid receptors on peripheral blood mononuclear 
cells (ie, lymphocytes and monocytes) and disturbances in 
the hypothalamic-pituitary-adrenal axis have been well docu-
mented in the disease (Nijhuis et al 1994). Initial clinical 
trials involving the treatment of patients with nonsteroidal 
anti-inﬂ  ammatory drugs (NSAIDs) prior to the development 
of AD have been suggested to inhibit the immune response. 
This might reduce the chance of developing the disease (Yip 
et al 2005). Some authors, however, suggest that NSAIDs 
have no effect in patients already suspected of having devel-
oped AD (Aisen et al 2003) and that treatment with a COX-2 
inhibitor increases the amount of Beta-amyloid in the brain 
(Kukart et al 2005).
It is obvious that immunosuppressive therapy cannot be 
prolonged and should be stopped after obtaining the opti-
mal possible improvement of the disease (Gąsiorowski and 
Leszek 1997). It is well know that classical cytostatic drugs 
exhibit genotoxic activity, which is the cost paid for their 
anticancer cytotoxic and cytostatic activities. Therefore it 
is necessary to look for new immunosuppressors, possibly 
natural ones, for instance those derived from plants, which 
display low toxic and genotoxic activities. Several reports 
have been published on the efﬁ  ciency of natural immunosup-
pressive drugs in AD treatment (Anekonda and Redy 2005). 
We tested a natural product isolated from ovine colostrum, 
proline-rich polypeptide (PRP) complex, called Colostrinin. 
The complex showed immunomodulatory properties in mice, 
rats, and chickens, inducing maturation and differentiation of 
thymocytes. Colostrinin was found to improve the outcome 
of AD patients with mild to moderate dementia (Leszek et al 
1999, 2002). In this context, the neuroprotective mechanisms 
of acetylocholinesterase inhibitors (AChE), eg, donepezil 
or galantamine are very important. Tokatori and colleagues 
(2006) found that donepezil and galantamine protect cortical 
neurons against acute glutamate treatment-induced neuro-
toxicity at steps before, and that tacrine protects at steps 
after nitric oxide radical formation. On the other hand the 
neuroprotective effects of donepezil and galantamine, but not 
tacrine, against neurotoxicity induced by moderate glutamate 
treatment were mediated through the phosphatidylinositol 3 
kinase-Akt pathway.
These ﬁ  ndings unveiled the hitherto unknown neuropro-
tective effects of therapeutic AChE inhibitors and provided 
valuable insights into its neuroprotective mechanisms. They 
may very likely form the basis for a novel treatment strategy 
against AD. Our experiments suggest that the mechanism 
of protection by donepezil may be related to histamine sig-
naling through the H1R and H2R receptors. We found that 
donepezil may restore the proper balance between H1R and 
H2R expression (Leszek et al 2004). In other experimental 
models of AD it was shown that such agents as monoamine 
oxidase type B(MAO-B) inhibitors and dopamine agonists 
exert a neuroprotective effect at the cellular, neurochemical, 
and functional levels. It has not, however, been possible to 
demonstrate an unequivocal neuroprotective of these sub-
stances in clinical studies (Gerlach et al 2000).
We hypothesize that an important risk factor of AD is 
the manifestation of immune aging. Immune aging increases 
susceptibility to the development of autoaggressive reactions, 
and several known and supposed etiological factors of AD 
may direct the elevated autoimmune reactions against brain 
tissue components. The focal inﬁ  ltration of brain tissue by 
immune cells and the concentrations of cytokines, inﬂ  am-
matory factors, and B-amyloid compress neuroﬁ  brils and 
neurons adjacent to senile plaques and thus interfere with 
their normal neurophysiological functions. Therefore, lower-
ing the deposited mass should lead to marked improvement 
of neurophysiological functions of neurons and neuroﬁ  brils 
compressed by it. This is possible with the use of immuno-
modulatory or immunosuppressive drugs.
Summing up, all the data presented above concerning 
a better understanding of the role of inﬂ  ammation in the 
development of many neurodegenerative diseases are, in our 
opinion, required before we can safety develop therapeutic 
strategies for preventing neuronal damage. Novel therapeutic 
approaches must rely on the regulation of endogenous anti-
inﬂ  ammatory pathways, identiﬁ  cation of early markers of 
neuronal deterioration, and a combination treatment involv-
ing immune modulation and anti-inﬂ  ammatory therapies.
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